

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PR60419USw		SERIAL NO. To be assigned 10/567,012		
				APPLICANT Neil Lee SPECTOR et al.				
				FILING DATE Concurrently herewith		GROUP To be assigned- 1643		
U.S. PATENT DOCUMENTS								
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate	
CJW ↓	1.	6,169,091	01/02/2001	COCKERILL et al.				
	2.	6,174,889	01/16/2001	COCKERILL et al.				
	3.	6,207,669	03/27/2001	COCKERILL et al.				
	4.	6,391,874	05/21/2002	COCKERILL et al.				
Continue on page _____								
FOREIGN PATENT DOCUMENTS								
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No	
	5.	WO 99/35146	07/15/1999	PCT			X	
	6.	WO 01/04111	01/18/2001	PCT			X	
	7.	WO 02/02552	01/10/2002	PCT			X	
	8.	WO 02/056912	07/25/2002	PCT			X	
Continue on page _____								
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)								
amh amh amh ↓ amh amh amh amh amh amh amh amh amh amh amh amh amh amh amh	9.	Bargmann et al., "Oncogenic activation of the <i>neu</i> -encoded receptor protein by point mutation and deletion," <i>EMBO</i> 7(7):2043-2052 (1988).						
	10.	Burris, "Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ERbB-2 inhibitor lapatinib," <i>The Oncologist</i> 9 Suppl. 3:10-15 (2004).						
	11.	Christianson et al., "NH <sub>2</sub> -terminally truncated HER-2/ <i>neu</i> protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer," <i>Cancer Research</i> 58(22):5123-5129 (Nov. 1998).						
	12.	Colomer et al., "Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer," <i>Clin. Cancer Research</i> 6(6):2356-2362 (Jun. 2000).						
	13.	DiFiore et al., " <i>erbB2</i> is a potent oncogene when overexpressed in NIH/3T3 cells," <i>Science</i> 237:178-182 (Jul. 1987).						
	14.	Harris et al., "Comparison of methods of measuring <i>HER-2</i> in metastatic breast cancer patients treated with high-dose chemotherapy," <i>J. Clin. Oncol.</i> 19(6):1698-1706 (Mar. 2001).						
	15.	Molina et al., "Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells," <i>Cancer Res.</i> 61(12):4744-4749 (Jun. 2001).						
	16.	Molina et al., "NH <sub>2</sub> -terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer," <i>Clin. Cancer Res.</i> 8(2):347-353 (Feb. 2002).						
	17.	Rusnak et al., "The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer," <i>Cancer Res.</i> 61(19):7196-7203 (Oct. 2001).						
	18.	Rusnak et al., "The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines <i>in Vitro</i> and <i>in Vivo</i> ," <i>Mol. Cancer Therap.</i> 1(2):85-94 (Dec. 2001).						
	19.	Segatto et al., "Different structural alterations upregulate <i>in vitro</i> tyrosine kinase activity and transforming potency of the <i>erbB-2</i> gene," <i>Mol. Cell. Biol.</i> 8(12):5570-5574 (Dec. 1988).						
	20.	Xia et al., "Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/ <i>erbB2</i> and downstream Erk1/2 and AKT pathways," <i>Oncogene</i> 21(41):6255-6263 (Sep. 2002).						
	21.	Xia, "Truncated ErbB2 receptor (p95 ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016," <i>x</i> 23(3):646-653 (Jan. 2004).						
	Continue on page _____							
	EXAMINER amh				DATE CONSIDERED 12/04/2007			
	EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

<b>SERIAL NO.</b>	10/567,012
<b>FILING DATE</b>	February 1, 2006
<b>APPLICANT</b>	Spector et al.
<b>GROUP</b>	1643
<b>EXAMINER</b>	A. M. Harris, Ph.D.
<b>ATTORNEY DOCKET NO.</b>	PR60419USw

[illegible][illegible][illegible]

EXAMINER Ann Hark

DATE CONSIDERED

11/15/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.